Endocrine Abstracts

Introduction: Obesity is a complex and multifactorial disease with a chronic and relapsing nature, and is associated with over 200 co-morbidities. In a minority of patients, the obesity is caused by gene defects in the leptin-melanocortin pathway. As lifestyle interventions often fail in these patients, additional anti-obesity pharmacotherapy is needed. In this case report, we describe the therapeutic journey of a patient with early-onset obesity and hyperphagia due to heteroz...

Introduction: Melanocortin-4 receptor (MC4R) is a G-protein-coupled receptor expressed in regions of the hypothalamus regulating appetite and energy expenditure. Extensive evidence from genetic and biological studies show that MC4R is a key player in the homeostatic regulation of body weight. MC4R loss of function (LoF) variants are the most common cause of monogenic obesity. We have identified 13 heterozygous MC4R variants in patients with obesity at our academic Obesity Cent...

Background: Obesity (BMI< 30 kg/m2) is a chronic and progressive disease, that is associated with many co-morbidities such as cardiovascular and psychiatric diseases, cancer, and arthritis. Lifestyle interventions are the cornerstone of obesity treatment, but when ineffective, anti-obesity pharmacotherapy could be added. In recent years, several anti-obesity agents have been approved, such as the glucagon-like peptide -1 (GLP-1) analogue liraglutide. Liraglutide...

IntroductionObesity is highly prevalent, comes with serious health burden and is difficult to treat. In a minority, there is a genetic cause for the obesity. In these patients, therapy-resistant obesity is often observed despite intensive lifestyle treatment. Moreover, it is still unclear whether bariatric surgery is less successful in genetic obesity. Liraglutide is a Glucagon-Like-Peptide-1 (GLP-1) receptor agonist or GLP-1 analogue, showing positive e...